Markets

Regeneron Pharmaceuticals (REGN) - Bull of the Day

A generic image of a pair of glasses on top of a calculator
Credit: Shutterstock photo

We are upgrading Regeneron Pharmaceuticals ( REGN ) to Outperform from Neutral ahead of its second quarter earnings results slated for July 25. Regeneron, which turned a profit in the first quarter of 2012, should continue performing well throughout 2012, driven by excellent growth prospects of Eylea.

We have increased our 2012 earnings estimates by $0.17 to $1.07 per share. Moreover, with three action dates and multiple pipeline related news lined up, the remainder of 2012 promises to be exciting for Regeneron, with a scope for significant stock price appreciation.

Consequently, we believe that the current price represents an attractive entry point for long-term investors. Based on 2012 sales estimates, the stock is trading at 10.8x, compared to the industry average of 4.2x. Our price target of $145.00 is based on P/S of 13.0x our 2012 sales estimate.

REGENERON PHARM (REGN): Free Stock Analysis Report

REGENERON PHARM (REGN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

REGN

Other Topics

Stocks

Latest Markets Videos